Mentrik Biotech, LLC is currently developing a next-generation, anti-CD20 monoclonal antibody, AME-133v. We are open to partnership and out-licensing opportunities for the molecule, as well as for future molecules in development.

We are seeking also currently seeking acquisition of additional molecules, in both oncology and autoimmune disease.